ClinicalTrials.gg
CompletedNCT03675685Updated Oct 6, 2020Results posted

Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP

A Phase 1 interventional study of CCH (collagenase clostridium histolyticum) in Edematous Fibrosclerotic Panniculopathy, sponsored by Endo Pharmaceuticals. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-06.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing Microbial Collagenase in Cellulite — none open to participants now, none under way, none of them phase 3. Microbial Collagenase · Cellulite.

Enrollment
14th of 15
12 · median 150
Started
2018
with 4 others
Phase 1
2 of 15
none open now
Registered
10th of 15
by date
Lead sponsor
14 of 15
Endo Pharmaceuticals

Among the 15 studies testing Microbial Collagenase in Cellulite, this one is the 14th largest by enrollment, is one of 5 that started in 2018, is one of 2 in phase 1, and was the 10th registered.

Cellulite

71 studies on the registry are indexed under Cellulite; 3 are open to participants now.

Browse Cellulite studies →

Open to participants now

None of the 15 studies testing Microbial Collagenase in Cellulite is open now. The open studies under Cellulite, anywhere →

Where they have run

About Microbial Collagenase

Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1 Cellulite study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing Microbial Collagenase in Cellulite as a file.
02

Study summary

This study will evaluate the safety and Pharmacokinetics (PK) of a single 3.36-mg dose of Collagenase Clostridium Histolyticum (CCH) in 4 quadrants concurrently, in subjects with Edematous fibrosclerotic panniculopathy (EFP).

This study will provide insight to the PK profile and safety of concurrent subcutaneous injections of CCH 0.84 mg/quadrant into 4 quadrants.

03

Conditions studied

  • Edematous Fibrosclerotic Panniculopathy

Browse trials for

Keywords

  • Cellulite
  • Edematous Fibrosclerotic Panniculopathy
  • EFP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • No subject will be dosed until all eligibility criteria have been satisfied. In order to be eligible to participate in the study, subjects must meet the following criteria:

    1. Be a female ≥18 years of age.
    2. Have evidence of cellulite within 4 quadrants (a quadrant is defined as a left buttock, right buttock, left posterolateral thigh or right posterolateral thigh) as assessed by the Investigator using the Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) at the Screening visit; has a score of 2 (mild), 3 (moderate) or 4 (severe) as reported by the Investigator (CR-PCSS) in 4 quadrants at the Screening visit.
    3. Have a (BMI) between 20.0 and 35.0 kg/m\^2, and intends to maintain stable body weight throughout the duration of the study (a variation of ≤10% from baseline body weight is permitted).
    4. Be willing to apply sunscreen to the dosing quadrants before each exposure to the sun while participating in the study (ie, screening through end of study).
    5. Be judged to be in good health, based upon the results of a medical history, physical examination, and laboratory profile at screening.
    6. Have a negative pregnancy test at the Screening visit and on Day -1 at admission (before injection of study drug); and be using an effective method (e.g., abstinence, intrauterine device [IUD], hormonal [estrogen/progestin] contraceptives, or double barrier control) for at least 1 menstrual cycle prior to study enrollment and for the duration of the study; or be menopausal defined as 12 months of amenorrhea in the absence of other biological or physiological causes, as determined by the Investigator; or for at least 1 year; or be surgically sterile (i.e., hysterectomy, bilateral oophorectomy, tubal ligation).
    7. Be willing and able to cooperate with the requirements of the study.
    8. Voluntarily sign and date an form approved by the Institutional Review Board/Independent Ethics Committee/Human Research Ethics Committee (IRB/IEC/HREC).

Exclusion criteria

Exclusion Criteria:

  • A subject will be excluded from study participation if she:

    1. Has any of the following systemic conditions:

      1. Coagulation disorder
      2. Evidence or history of (other than excised basal-cell carcinoma) unless there has been no recurrence in at least 5 years
      3. History of keloidal scarring or abnormal wound healing
      4. Concurrent diseases or conditions that might interfere with the conduct of the study, confound the interpretation of the study results, or endanger the subject's well-being. Any questions about concurrent diseases should be discussed with the Medical Monitor.
      5. Evidence of abnormalities on physical examination, vital signs, (ECG), or clinical laboratory values.
    2. Has any of the following local conditions in the areas to be treated:

      1. History of lower extremity thrombosis or post-thrombosis syndrome
      2. Vascular disorder (e.g., varicose veins) in areas to be treated
      3. Inflammation or active infection
      4. Active cutaneous alteration including rash, eczema, psoriasis, or skin cancer
      5. Has a tattoo located within 2 cm of the site of injection
    3. Requires the following concomitant medications before or during participation in the trial:

      a. Anticoagulant or antiplatelet medication or has received anticoagulant or antiplatelet medication (except for ≤150 mg aspirin daily) within 7 days before injection of study drug

    4. Has a positive test on a urine drug screen for drugs of abuse
    5. Has a history of drug or alcohol abuse
    6. Has used any of the following for the treatment of EFP on the legs or buttock within the timelines identified below or intends to use any of the following at any time during the course of the study:

      1. Liposuction within the treatment quadrants during the 12-month period before injection of study drug
      2. Injections (e.g., mesotherapy); radiofrequency device treatments; laser treatment; or surgery (including subcision and/or powered subcision) within the treatment quadrants during the 12-month period before injection of study drug
      3. Endermologie or similar treatments within the treatment quadrants during the 6-month period before injection of study drug
      4. Massage therapy within the treatment quadrants during the 3-month period before injection of study drug
      5. Creams (e.g., Celluvera™, TriLastin®) to prevent or mitigate EFP within the treatment quadrants during the 2-week period before injection of study drug
    7. Is presently nursing a baby or providing breast milk for a baby
    8. Intends to become pregnant during the study
    9. Intends to initiate an intensive sport or exercise program during the study
    10. Intends to initiate a weight reduction program during the study
    11. Has received an drug or treatment within 30 days before injection of study drug
    12. Has a known systemic allergy to collagenase or any other of study drug
    13. Has received any collagenase treatments at any time prior to treatment
    14. Has been a subject in a previous cellulite clinical trial of CCH: AUX-CC-830, AUX-CC-831, EN3835-102, EN3835-104, EN3835-201, EN3835-202, EN3835-205, EN3835-302, EN3835-303, EN3835-304, and/or EN3835-209.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    CCH (Collagenase clostridium histolyticum)

    Biological: CCH (collagenase clostridium histolyticum)

Interventions

  • A single dose of 3.36 mg of CCH will be administered as subcutaneous injections (CCH 0.84 mg) per quadrant concurrently in 4 quadrants. A quadrant is defined as one of the following: left buttock, right buttock, left posterolateral thigh, or right posterolateral thigh.

06

What researchers measure

Primary outcomes

  1. Plasma AUX-I and AUX-II Concentrations

    Determine if there is systemic exposure following a subcutaneous single dose of Collagenase clostridium histolyticum (CCH) (3.36 mg) as 12 injections per quadrant in 4 quadrants concurrently (0.84 mg per quadrant) in adult women with Edematous Fibrosclerotic Panniculopathy (EFP). There were no quantifiable levels of plasma AUX-I or AUX-II observed at any collection time point following subcutaneous injection of EN3835. As a result, no pharmacokinetic (PK) parameters were calculated.

    Time frame: Day 1 to Day 22

  2. Investigator CR-PCSS Rating

    Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) scores for each quadrant are based on the investigator's CR-PCSS evaluation done at the Screening visit (Baseline) and at End of Study (Day 22). CR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe). Negative change reflects an improvement in cellulite severity; positive change reflects a worsening in cellulite severity.

    Time frame: Day 1 to Day 22

  3. Investigator CR-PCSS Change From Baseline

    Change from Baseline (Day 22 - Baseline). Baseline Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) scores for each quadrant are based on the investigator's CR-PCSS evaluation done at the Screening visit. CR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe). Negative change reflects an improvement in cellulite severity; positive change reflects a worsening in cellulite severity.

    Time frame: Day 1 to Day 22

  4. Investigator CR-PCSS Responder Analysis at End of Study

    Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) scores for each quadrant are based on the investigator's CR-PCSS evaluation at the end of study. CR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe). A 2-point responder is a participant with a reduction of cellulite severity by at least 2 severity levels from baseline to end of study (i.e., change from baseline CR-PCSS rating of -2, -3, or -4). A 1-point responder is a participant with a reduction of cellulite severity by at least 1 severity level from baseline to end of study (i.e., change from baseline CR-PCSS rating of -1, -2, -3, or -4).

    Time frame: Day 22

07

Results

Posted Oct 6, 2020

Participant flow

Participant flow — Overall Study
MilestoneCCH (Collagenase Clostridium Histolyticum)
Started12
Completed12
Not completed0

Outcome measures

PrimaryPlasma AUX-I and AUX-II Concentrations

Determine if there is systemic exposure following a subcutaneous single dose of Collagenase clostridium histolyticum (CCH) (3.36 mg) as 12 injections per quadrant in 4 quadrants concurrently (0.84 mg per quadrant) in adult women with Edematous Fibrosclerotic Panniculopathy (EFP). There were no quantifiable levels of plasma AUX-I or AUX-II observed at any collection time point following subcutaneous injection of EN3835. As a result, no pharmacokinetic (PK) parameters were calculated.

Time frame:
Day 1 to Day 22
Reported as:
Mean · mmol/L
Plasma AUX-I and AUX-II Concentrations
mmol/LCCH (Collagenase Clostridium Histolyticum)
Plasma AUX-I and AUX-II ConcentrationsNA ± NA
PrimaryInvestigator CR-PCSS Rating

Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) scores for each quadrant are based on the investigator's CR-PCSS evaluation done at the Screening visit (Baseline) and at End of Study (Day 22). CR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe). Negative change reflects an improvement in cellulite severity; positive change reflects a worsening in cellulite severity.

Time frame:
Day 1 to Day 22
Reported as:
Count of participants · Participants
Investigator CR-PCSS Rating
ParticipantsLeft ButtockRight ButtockLeft ThighRight Thigh
Screening (Baseline) — None (0)0000
Screening (Baseline) — Almost None (1)0000
Screening (Baseline) — Mild (2)6488
Screening (Baseline) — Moderate (3)4633
Screening (Baseline) — Severe (4)1100
Day 22 (End of Study) — None (0)0000
Day 22 (End of Study) — Almost None (1)1255
Day 22 (End of Study) — Mild (2)7654
Day 22 (End of Study) — Moderate (3)3112
Day 22 (End of Study) — Severe (4)0200
PrimaryInvestigator CR-PCSS Change From Baseline

Change from Baseline (Day 22 - Baseline). Baseline Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) scores for each quadrant are based on the investigator's CR-PCSS evaluation done at the Screening visit. CR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe). Negative change reflects an improvement in cellulite severity; positive change reflects a worsening in cellulite severity.

Time frame:
Day 1 to Day 22
Reported as:
Count of participants · Participants
Investigator CR-PCSS Change From Baseline
ParticipantsLeft ButtockRight ButtockLeft ThighRight Thigh
-40000
-30000
-20110
-15457
05553
+11101
+20000
PrimaryInvestigator CR-PCSS Responder Analysis at End of Study

Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) scores for each quadrant are based on the investigator's CR-PCSS evaluation at the end of study. CR-PCSS is a 5-level scale ranging from "0" (None) to "4" (Severe). A 2-point responder is a participant with a reduction of cellulite severity by at least 2 severity levels from baseline to end of study (i.e., change from baseline CR-PCSS rating of -2, -3, or -4). A 1-point responder is a participant with a reduction of cellulite severity by at least 1 severity level from baseline to end of study (i.e., change from baseline CR-PCSS rating of -1, -2, -3, or -4).

Time frame:
Day 22
Reported as:
Count of participants · Participants
Investigator CR-PCSS Responder Analysis at End of Study
ParticipantsLeft ButtockRight ButtockLeft ThighRight Thigh
2-point Responder — Yes0110
2-point Responder — No11101011
1-point Responder — Yes5567
1-point Responder — No6654

Adverse events

Collected over All (serious and nonserious) AEs, from Day 1 up to Day 22. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CCH (Collagenase Clostridium Histolyticum)0/12 (0%)0/12 (0%)12/12 (100%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventCCH (Collagenase Clostridium Histolyticum)
Injection site bruisingGeneral disorders12/12
Injection site painGeneral disorders12/12
Injection site oedemaGeneral disorders4/12
Injection site swellingGeneral disorders2/12
HeadacheNervous system disorders2/12
ChillsGeneral disorders1/12
Injection site erythemaGeneral disorders1/12
Injection site noduleGeneral disorders1/12
Injection site pruritusGeneral disorders1/12
Injection site warmthGeneral disorders1/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)CCH (Collagenase Clostridium Histolyticum)
Mean49.3 ± 10.19
Sex: Female, Male
Sex: Female, Male(Participants)CCH (Collagenase Clostridium Histolyticum)
Female12
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CCH (Collagenase Clostridium Histolyticum)
Hispanic or Latino2
Not Hispanic or Latino10
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CCH (Collagenase Clostridium Histolyticum)
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American4
White6
More than one race1
Unknown or Not Reported0
Body Mass Index (BMI)
Body Mass Index (BMI)((kg/m^2))CCH (Collagenase Clostridium Histolyticum)
Mean29.94 ± 3.574
Skin Category (Fitzpatrick Scale)
Skin Category (Fitzpatrick Scale)(Participants)CCH (Collagenase Clostridium Histolyticum)
I (Pale White)0
II (Fair)1
III (Darker White)4
IV (Light Brown)3
V (Brown)1
VI (Dark Brown or Black)3
08

Study locations

1 site
  • Endo Clinical Trial Site #1
    Baltimore, Maryland 21201, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Nov 2018, 1 month.

Results were first posted in Oct 2020, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2018
First posted
Sep 18, 2018
StartActual
Sep 18, 2018
Primary completionActual
Nov 1, 2018
CompletionActual
Nov 1, 2018
Results first posted
Oct 6, 2020
Last update
Oct 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03675685
Responsible party
Sponsor
First posted
Sep 18, 2018
Start date
Sep 18, 2018
Primary completion
Nov 1, 2018
Completion
Nov 1, 2018
Results posted
Oct 6, 2020
Last update
Oct 6, 2020

Study contacts

Saji Vijayan, MD
study director · Endo Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion